{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT02989584","nct_id":"NCT02989584","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02989584. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"This is a two phase study with a single study arm for each phase.\n\nFor Phase 1: Following enrollment participants will be treated with combination therapy on a 21 day cycle x 6 cycles. Gemcitabine (1000 mg/m2 on Day 1 and Day 8), cisplatin (70 mg/m2 on Day 1), and atezolizumab (1200 mg on Day 8) will be administered intravenously.\n\nPhase 2: Following enrollment participants will be treated with a single dose of atezolizumab alone followed by combination therapy on a 21-day cycle x 4 cycles, followed by a single dose of atezolizumab alone. Gemcitabine 1000mg/m2, cisplatin (70 mg/m2 on Day 1), and atezolizumab (1200 mg on Day 8) will be administered intravenously.","label":"Atezolizumab, Gemcitabine, Cisplatin","type":"EXPERIMENTAL"}],"collaborators":["Genentech, Inc."],"completion_date":{"date":"2026-12","type":"ESTIMATED"},"conditions":["Bladder Cancer","Metastatic Bladder Cancer","Urothelial Carcinoma"],"enrollment":{"count":54,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Atezolizumab","otherNames":[],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-26","lead_sponsor":"Memorial Sloan Kettering Cancer Center","official_title":"A Pilot Safety Study and Single Arm Phase II Study of Gemcitabine and Cisplatin With Atezolizumab (MPDL3280A) in Patients With Metastatic and Muscle Invasive Bladder Cancer, Respectively","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Test the safety of atezolizumab in combination with gemcitabine/cisplatin as assessed by dose limiting toxicity rate.","timeFrame":"Participants will be followed for survival until 5 years from treatment completion or until disease recurrence/progression."}],"references":[{"citation":"Funt SA, Lattanzi M, Whiting K, Al-Ahmadie H, Quinlan C, Teo MY, Lee CH, Aggen D, Zimmerman D, McHugh D, Apollo A, Durdin TD, Truong H, Kamradt J, Khalil M, Lash B, Ostrovnaya I, McCoy AS, Hettich G, Regazzi A, Jihad M, Ratna N, Boswell A, Francese K, Yang Y, Folefac E, Herr HW, Donat SM, Pietzak E, Cha EK, Donahue TF, Goh AC, Huang WC, Bajorin DF, Iyer G, Bochner BH, Balar AV, Mortazavi A, Rosenberg JE. Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial. J Clin Oncol. 2022 Apr 20;40(12):1312-1322. doi: 10.1200/JCO.21.01485. Epub 2022 Jan 28.","pmid":"35089812","type":"DERIVED"}],"start_date":{"date":"2016-12-20"},"study_type":"INTERVENTIONAL","title":"A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer","url":"https://clinicaltrials.gov/study/NCT02989584"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02989584"}